Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Autor: Weiss, J.M., Csoszi, T., Maglakelidze, M., Hoyer, R.J., Beck, J.T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C.M., Boccia, R.V., Hanna, W., Nikolinakos, P., Chiu, V.K., Owonikoko, T.K., Schuster, S.R., Hussein, M.A., Richards, D.A., Sawrycki, P., Bulat, I., Hamm, J.T., Hart, L.L., Adler, S., Antal, J.M., Lai, A.Y., Sorrentino, J.A., Yang, Z., Malik, R.K., Morris, S.R., Roberts, P.J., Dragnev, K.H. *
Zdroj: In Annals of Oncology October 2019 30(10):1613-1621
Databáze: ScienceDirect